2018

1. Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: Pooled analysis in 4 basque country university hospitals

   ClinicoEconomics and Outcomes Research, Vol. 10, pp. 189-199